Cognoptix Reports Positive Results for Trial of Simple Eye Test for Alzheimer's


Cognoptix announced that it has developed a simple eye test that has the potential to change the way that Alzheimer’s disease is detected and managed. The company conducted a multi-site clinical trial of its Sapphire II eye test designed to identify Alzheimer’s disease patients via a beta-amyloid (Ab) signature in their eyes. By detecting a specific fluorescent signature of ligand-marked Ab in the supranucleus region of the human lens, Sapphire II achieved a sensitivity of 85 percent and a specificity of 95 percent in differentiating 20 patients who were clinically diagnosed with probable Alzheimer’s Disease (AD) from a group of 20 age-matched healthy volunteers. These results validate the previous proof-of-concept clinical trial of the Cognoptix drug/device combination eye test, according to Cognoptix.